What is Biorelate?
Biorelate specializes in advanced data curation technology, providing the biopharmaceutical industry with the tools necessary to identify and validate novel drug targets. At the heart of its offering is Galactic AI, a sophisticated knowledge graph that synthesizes causal insights from disparate, high-volume sources. This platform enables bioinformatics professionals to map intricate target-drug-disease relationships with unprecedented precision. By streamlining the research process, Biorelate serves a diverse clientele ranging from multinational pharmaceutical giants to agile, innovative biotech firms. The company's market position is defined by its ability to bridge the gap between raw biological data and actionable intelligence, thereby accelerating the drug development lifecycle and enhancing critical decision-making processes for its partners.
How much funding has Biorelate raised?
Biorelate has raised a total of $6.5M across 1 funding round:
Series A
$6.5M
Series A (2022): $6.5M with participation from Maven Capital Partners UK, Manchester Technology Fund, Triple Point Ventures, and YFM Equity Partners
Key Investors in Biorelate
Maven Capital Partners UK
A prominent venture capital and private equity firm that provides strategic growth capital to high-potential businesses across the United Kingdom.
Manchester Technology Fund
An investment fund dedicated to supporting early-stage spin-out companies originating from the University of Manchester, with a strong focus on life sciences and IT.
Triple Point Ventures
A venture firm specializing in B2B software investments, with a particular focus on AI, healthcare, and data-driven startups in high-growth markets.
What's next for Biorelate?
With the recent capital infusion, Biorelate is poised to accelerate its product roadmap and expand its market reach. The strategic focus will likely center on enhancing the predictive capabilities of Galactic AI, ensuring that the platform remains at the vanguard of the drug discovery revolution. As the company scales, it will continue to prioritize the integration of new data streams and the expansion of its client base, further embedding its technology into the workflows of global pharmaceutical leaders. The firm's trajectory suggests a move toward broader industry adoption, potentially setting new standards for how data-driven insights are utilized in the pursuit of therapeutic breakthroughs.
See full Biorelate company page
